Add a listing
    Add a listing

    Weatherwax Bio

      drug discovery platform company developing the next generation of induced-proximity medicine

    General
    • Headquarters

      San Francisco, California, United States

    • Founders & Team

      Armand Cognetta, Matthias Pauthner

    • Year Founded

      2019

    • Number of employees

      50

    • Company type

      Private company

    • Funding stage

      Seed

    • Investors

      The Longevity Fund, Y Combinator

    Technical Details
    • Aging Target

      Loss of proteostasis

    • Product modality

      multispecifics

    About

    Weatherwax Biotechnologies is a seed-stage drug discovery platform company developing the next generation of induced-proximity medicines. The founders, Armand Cognetta and Matthias Pauthner, earned their PhD’s at Scripps Research in San Diego in the renowned labs of Ben Cravatt and Dennis Burton, and published a combined 50+ papers in high ranking academic journals, including Cell, Nature, Science and The New England Journal of Medicine, and additionally hold numerous patents in the drug discovery space. Weatherwax further has a remarkable board of advisors including Martin Babler, John Clarke, Laura Deming, Uri Lopatin, Brent Stockwell as well as other high ranking academic and industry opinion leaders.

    Categories

    How much is an extra decade of life worth to you? Make a bet on longevity science today.

    Donate to Impetus Grants

    You May Also Be Interested In